BR112015023469A8 - toxóides, composições e métodos relacionados - Google Patents

toxóides, composições e métodos relacionados Download PDF

Info

Publication number
BR112015023469A8
BR112015023469A8 BR112015023469A BR112015023469A BR112015023469A8 BR 112015023469 A8 BR112015023469 A8 BR 112015023469A8 BR 112015023469 A BR112015023469 A BR 112015023469A BR 112015023469 A BR112015023469 A BR 112015023469A BR 112015023469 A8 BR112015023469 A8 BR 112015023469A8
Authority
BR
Brazil
Prior art keywords
methods
toxoids
compositions
toxins
toxin
Prior art date
Application number
BR112015023469A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015023469A2 (pt
Inventor
Shieh Mark
Soika Mike
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015023469(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of BR112015023469A2 publication Critical patent/BR112015023469A2/pt
Publication of BR112015023469A8 publication Critical patent/BR112015023469A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
BR112015023469A 2013-03-15 2014-03-14 toxóides, composições e métodos relacionados BR112015023469A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361793376P 2013-03-15 2013-03-15
PCT/US2014/029070 WO2014144594A1 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (2)

Publication Number Publication Date
BR112015023469A2 BR112015023469A2 (pt) 2017-07-18
BR112015023469A8 true BR112015023469A8 (pt) 2019-12-03

Family

ID=50489432

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023469A BR112015023469A8 (pt) 2013-03-15 2014-03-14 toxóides, composições e métodos relacionados

Country Status (13)

Country Link
US (1) US20160030542A1 (https=)
EP (1) EP2970400A1 (https=)
JP (1) JP2016519671A (https=)
KR (1) KR20150133771A (https=)
CN (1) CN105308066A (https=)
AR (1) AR095668A1 (https=)
AU (2) AU2014228983B2 (https=)
BR (1) BR112015023469A8 (https=)
CA (1) CA2907156A1 (https=)
HK (1) HK1213917A1 (https=)
SG (1) SG11201507578PA (https=)
TW (1) TW201518316A (https=)
WO (1) WO2014144594A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6691477B2 (ja) * 2013-06-14 2020-04-28 サノフィ パストゥール インコーポレイテッド クロストリジウム・ディフィシル（ｃ．ｄｉｆｆｉｃｉｌｅ）に対して免疫する組成物及び方法
CN108003224A (zh) * 2017-12-20 2018-05-08 天康生物股份有限公司 一种多杀性巴氏杆菌毒素蛋白的纯化方法
US20250213667A1 (en) 2022-06-01 2025-07-03 Valneva Austria Gmbh Clostridium difficile vaccine
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
MX2010001054A (es) 2007-07-26 2010-04-21 Sanofi Pasteur Ltd Composiciones adyuvantes antigenicas y metodos.
HUE037932T2 (hu) 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Also Published As

Publication number Publication date
AR095668A1 (es) 2015-11-04
SG11201507578PA (en) 2015-10-29
CA2907156A1 (en) 2014-09-18
AU2018204879A1 (en) 2018-07-26
US20160030542A1 (en) 2016-02-04
KR20150133771A (ko) 2015-11-30
CN105308066A (zh) 2016-02-03
AU2014228983A1 (en) 2015-10-08
JP2016519671A (ja) 2016-07-07
TW201518316A (zh) 2015-05-16
WO2014144594A1 (en) 2014-09-18
AU2014228983B2 (en) 2018-04-05
WO2014144594A8 (en) 2014-11-13
EP2970400A1 (en) 2016-01-20
BR112015023469A2 (pt) 2017-07-18
HK1213917A1 (zh) 2016-07-15

Similar Documents

Publication Publication Date Title
MX361727B (es) Variantes de polipeptido ph20, formulaciones y usos de las mismas.
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
CO7121348A2 (es) Proteínas de fusión de interleuquina-2 y usos de las mismas
PH12019500989A1 (en) Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
PH12020550927A1 (en) Therapeutic enzyme fusion protein having novel structure and use thereof
BR112015023472A2 (pt) método de produção de um produto químico, método de bioprodução de um produto químico, organismo geneticamente modificado e produto
BR112016012883A2 (pt) Métodos e composições para aprimorar o rendimento de milho
DOP2013000235A (es) Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae.
MX351074B (es) Vacunas contra clostridium difficile que comprenden toxinas recombinantes.
MX2016009072A (es) Fusion de antigenos micobacterianos heterooligomericos.
MX368142B (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
BR112017005997A2 (pt) método
BR112016016539A2 (pt) micro-organismos recombinantes enriquecidos com carboidratos
BR112015023447A2 (pt) purificação de proteínas helicoidais triplas
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
BR112015023469A8 (pt) toxóides, composições e métodos relacionados
BR112015023332A2 (pt) Toxóide, composições e método relacionados
BR112014018732A8 (pt) Composições imunogênicas contra campylobacter e usos das mesmas
IN2012DE00622A (https=)
AU2015348922A8 (en) Codon optimized polynucleotide for high level expression of CRM197
MX376782B (es) Métodos de administración de composiciones de amantadina.
BR112016002462A8 (pt) Métodos para melhorar os sintomas da asma usando benralizumabe
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
BR112016017242A2 (pt) Vetores lentivirais para gerar respostas imunes contra o vírus linfotrópico-t humano do tipo 1
BR112016027884A2 (pt) variante de xilanase da família 11 de gh, polinucleotídeo, construção de ácido nucleico, vetor de expressão, célula hospedeira, e, métodos de produção de uma variante de xilanase da família 11 de gh e de degradação de um material

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements